Distinguished in Teratocarcinosarcoma

Dr. Roger B. Cohen

Oncology
Penn Medicine
Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Distinguished in Teratocarcinosarcoma
Penn Medicine
Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roger Cohen is an Oncologist in Philadelphia, Pennsylvania. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Endoscopy. Dr. Cohen is currently accepting new patients.

His clinical research consists of co-authoring 212 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Harvard Medical School
Residency
Mount Sinai Medical Center
Specialties
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology, 1993
Hematology, 1986
Internal Medicine, 1984
Fellowships
Mount Sinai Medical Center
National Cancer Institute
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male
Awards
Recognized annually in Philadelphia magazine's Top Docs issue from 2011 through 2025

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, Philadelphia, PA 19104
Call: 215-615-5858

Additional Areas of Focus

Dr. Cohen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: April 03, 2023
Intervention Type: Drug
Study Drugs: CDX-3379, Cetuximab
Study Phase: Phase 2
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: CDK-002
Study Phase: Phase 1/Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of LY2801653 in Patients With Advanced Cancer
A Phase 1 Study of LY2801653 in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: February 20, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

212 Total Publications

Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study.
Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study.
Journal: Clinical and translational radiation oncology
Published: September 02, 2025
View All 212 Publications
Similar Doctors
Distinguished in Teratocarcinosarcoma
Dr. Tara C. Mitchell
Oncology
Distinguished in Teratocarcinosarcoma
Dr. Tara C. Mitchell
Oncology

Abramson Cancer Center Perelman 3rd Floor West

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Mitchell is an Oncologist in Philadelphia, Pennsylvania. Dr. Mitchell is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Olfactory Neuroblastoma, and Teratocarcinosarcoma. Dr. Mitchell is currently accepting new patients.

Anthony P. Scarpaci
Distinguished in Teratocarcinosarcoma
Dr. Anthony P. Scarpaci
Oncology | Hematology
Distinguished in Teratocarcinosarcoma
Dr. Anthony P. Scarpaci
Oncology | Hematology

Medical Oncology & Infusion Suite - 900 Medical Center Drive

900 Medical Center Drive, Suite 200, 
Sewell, NJ 
 (15.9 miles away)
856-557-7900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Scarpaci is a Hematologist and an Oncologist in Sewell, New Jersey. Dr. Scarpaci is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Olfactory Neuroblastoma, Teratocarcinosarcoma, Sinus Cancer, and Paget Disease of the Breast. Dr. Scarpaci is currently accepting new patients.

Rita S. Axelrod
Advanced in Teratocarcinosarcoma
Dr. Rita S. Axelrod
Oncology
Advanced in Teratocarcinosarcoma
Dr. Rita S. Axelrod
Oncology

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (1.8 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rita Axelrod is an Oncologist in Philadelphia, Pennsylvania. Dr. Axelrod is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Axelrod is currently accepting new patients.

VIEW MORE TERATOCARCINOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cohen's expertise for a condition
ConditionClose
  • Elite
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Cohen is
    Elite
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
  • Lung Cancer
    Dr. Cohen is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Cohen is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Cohen is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Cohen is
    Distinguished
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Cohen is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Laryngeal Cancer
    Dr. Cohen is
    Distinguished
    . Learn about Laryngeal Cancer.
    See more Laryngeal Cancer experts
  • Lung Adenocarcinoma
    Dr. Cohen is
    Distinguished
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Nasopharyngeal Carcinoma
    Dr. Cohen is
    Distinguished
    . Learn about Nasopharyngeal Carcinoma.
    See more Nasopharyngeal Carcinoma experts
View All 15 Distinguished Conditions
  • Advanced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Cohen is
    Advanced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. Cohen is
    Advanced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Anal Cancer
    Dr. Cohen is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Epithelial-Myoepithelial Carcinoma
    Dr. Cohen is
    Advanced
    . Learn about Epithelial-Myoepithelial Carcinoma.
    See more Epithelial-Myoepithelial Carcinoma experts
  • Glioma
    Dr. Cohen is
    Advanced
    . Learn about Glioma.
    See more Glioma experts
  • Lacrimal Gland Tumor
    Dr. Cohen is
    Advanced
    . Learn about Lacrimal Gland Tumor.
    See more Lacrimal Gland Tumor experts
View All 15 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Cohen is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Cohen is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Alveolar Soft Part Sarcoma
    Dr. Cohen is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anaplastic Thyroid Cancer
    Dr. Cohen is
    Experienced
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
  • Angiosarcoma
    Dr. Cohen is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Angiosarcoma of the Scalp
    Dr. Cohen is
    Experienced
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
View All 56 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.